mRNA Vaccine

An mRNA vaccine delivers a synthetic messenger RNA that instructs the recipient's own cells to transiently produce a target antigen, usually a pathogen surface protein, which the immune system then learns to recognise. The mRNA is typically packaged in lipid nanoparticles that protect it and enable cellular uptake; it does not enter the cell nucleus or alter the genome and is degraded after the antigen is made.

Definition

An mRNA vaccine is a nucleic-acid vaccine that delivers messenger RNA encoding a target antigen so that the vaccinated person's cells transiently express that antigen and mount a protective adaptive immune response against it.

Scope

This entry covers how mRNA vaccines encode and deliver an antigen, the immune responses they elicit, and the delivery and stability features that distinguish the platform. It is a platform-level reference within vaccine types and does not provide schedules, dosing, or individual immunisation advice.

Core questions

• How does delivered mRNA lead the body's own cells to produce a vaccine antigen?
• What role do lipid nanoparticles and nucleoside modifications play in delivery and tolerability?
• Why can mRNA vaccines elicit both antibody and T-cell responses?
• What stability and cold-chain considerations are characteristic of the platform?

Key concepts

• In situ antigen expression
• Lipid nanoparticle delivery
• Modified nucleosides
• Antibody and T-cell (including TH1) responses
• Transient, non-integrating mRNA
• Rapid, sequence-driven manufacturing
• Cold-chain and stability requirements

Mechanisms

The vaccine supplies an mRNA transcript encoding the chosen antigen, commonly formulated with modified nucleosides to limit unwanted innate activation and packaged in lipid nanoparticles that shield the RNA and promote uptake into cells. Once inside the cytoplasm the mRNA is translated by the cell's ribosomes into the antigen, which is then displayed to and recognised by the immune system, eliciting both antibody and T-cell responses, including TH1-skewed CD4 and CD8 T-cell activity. The mRNA remains in the cytoplasm, does not integrate into DNA, and is degraded by normal cellular processes after the antigen is produced. Because only the antigen sequence changes between targets, the platform supports rapid, standardised manufacturing.

Clinical relevance

mRNA vaccines reached large-scale human use during the COVID-19 pandemic, where randomised trials demonstrated high efficacy for two such products, establishing the platform clinically. This entry describes how the platform works and how its immunity is generated; it is not a basis for individual immunisation decisions, which follow current schedules and official guidance.

Evidence & guidelines

Large randomised controlled trials reported high efficacy for mRNA COVID-19 vaccines, and the platform's principles, delivery, and immunology are synthesised in vaccinology reviews. Product-specific recommendations are issued by the World Health Organization and national immunisation advisory bodies.

History

The platform builds on decades of work showing that in vitro–transcribed mRNA could direct protein expression in cells, followed by advances in nucleoside modification and lipid nanoparticle delivery that improved translation and tolerability. These foundations enabled the rapid development and authorisation of mRNA vaccines during the COVID-19 pandemic, the platform's first widespread clinical deployment.

Key figures

• Katalin Karikó
• Drew Weissman
• Norbert Pardi
• Uğur Şahin

Seminal works

• pardi-2018
• polack-2020
• baden-2021

Frequently asked questions

Does an mRNA vaccine change a person's DNA?

No. The mRNA stays in the cell's cytoplasm, does not enter the nucleus where DNA is kept, and is broken down after the antigen is made; it does not integrate into or alter the genome.

Why are mRNA vaccines often described as fast to develop?

Because only the encoded antigen sequence needs to change between targets, the same manufacturing process can be reused, allowing a new candidate to be produced once the target sequence is known.